Summary:
In patients with and without diabetes who are at risk for cardiovascular and renal complications, long-acting calcium channel blockers aimed at reducing blood pressure variability demonstrated significant improvements in cardiovascular and renal outcomes, especially among patients with diabetes compared to other antihypertensive treatment strategies without targeted reduction of blood pressure variability, supporting incorporation of blood pressure variability into risk assessments.
| PICO | Description |
|---|---|
| Population | Patients with and without diabetes who are at risk for cardiovascular and renal complications as studied in the Anglo-Scandinavian Cardiac Outcomes Trial. |
| Intervention | Use of long-acting calcium channel blockers (such as amlodipine) aimed at reducing blood pressure variability. |
| Comparison | Other antihypertensive treatment strategies without targeted reduction of blood pressure variability, including non-calcium channel blocker regimens. |
| Outcome | Long-term reduction in blood pressure variability with long-acting calcium channel blockers was associated with significant improvements in cardiovascular and renal outcomes, especially among patients with diabetes. Incorporation of blood pressure variability into risk assessments is recommended. |
Clinical Context
Blood pressure management in diabetes has traditionally focused on achieving target levels. However, emerging evidence suggests that blood pressure variability—the fluctuation in BP readings over time—may be an independent risk factor for cardiovascular and renal complications.
Patients with diabetes may be particularly vulnerable to BP variability effects due to diabetic autonomic neuropathy, arterial stiffness, and nephropathy.
Clinical Pearls
1. Variability Matters Beyond Mean BP: Two patients with identical average blood pressure may have very different outcomes if one has stable readings and the other shows marked fluctuation.
2. Long-Acting CCBs May Offer Variability Advantage: Long-acting calcium channel blockers like amlodipine provide consistent 24-hour blood pressure control, reducing peaks and troughs that contribute to variability.
3. Diabetes Amplifies Variability Risk: Diabetic autonomic dysfunction, arterial stiffness, and nephropathy all contribute to both increased variability and vulnerability to its consequences.
4. Renal Protection Is Part of the Story: The improvement in renal outcomes with variability reduction adds another argument for optimizing BP stability.
Practical Application
For patients with diabetes and hypertension, consider BP variability when selecting antihypertensive agents. Long-acting calcium channel blockers may offer advantages for patients with high variability.
Assess variability by reviewing sequential office BP readings. High variability (SD >15 mmHg or CV >10%) should prompt investigation and consideration of treatment optimization.
Broader Evidence Context
Multiple studies have confirmed visit-to-visit BP variability as a cardiovascular risk factor independent of mean BP. Current guidelines emphasize BP targets but do not yet formally incorporate variability into treatment algorithms.
Study Limitations
Post-hoc analysis of trial data cannot establish causation. CCB side effects not detailed. Optimal variability thresholds not defined.
Bottom Line
Blood pressure variability is an independent predictor of cardiovascular and renal outcomes, with particularly strong effects in patients with diabetes. Long-acting calcium channel blockers reduce BP variability and improve outcomes.
Source: Somayeh Rostamian, et al. “The impact of blood pressure variability on cardiovascular and renal outcomes in patients with and without diabetes: insights from the Anglo-Scandinavian Cardiac Outcomes Trial.” Read article
